Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections.

Trial Profile

A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doripenem (Primary) ; Cefepime
  • Indications Bacterial infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development

Most Recent Events

  • 01 Jul 2014 The primary endpoint has been changed from adverse events to number of participants with clinical cure rate at test of cure visit, according to ClinicalTrials.gov record.
  • 20 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
  • 03 Nov 2011 Planned End Date changed from 1 Mar 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top